9d • General discussion
Adipotide (FTPP): The Proapoptotic Peptide That Targets Fat at the Source
❇️ Adipotide might be the most mechanistically aggressive fat-loss compound in the research peptide space — and that's not hyperbole. Rather than suppressing appetite or boosting metabolism, it takes a more direct approach: it cuts off the blood supply to white adipose tissue entirely. The results in primate research were striking. So were some of the safety signals. Here's what the science actually shows.
❇️ The Mechanism: Starving Fat of Its Blood Supply
Adipotide — formally known as FTPP (Prohibitin-Targeting Peptide 1) — is a chimeric peptidomimetic compound originally developed at MD Anderson Cancer Center by researchers Wadih Arap and Renata Pasqualini. It was initially explored as a cancer treatment, designed to destroy tumor vasculature. Researchers then recognized the same targeting principle could apply to the blood vessels feeding white adipose tissue.
The peptide has two functional domains working in tandem. The targeting domain (CKGGRAKDC) binds to prohibitin, a protein selectively expressed on the surface of blood vessels supplying white fat. Once docked, the pro-apoptotic domain (D(KLAKLAK)2) triggers programmed cell death in those vascular cells. Without a blood supply, the surrounding adipocytes undergo apoptosis and are reabsorbed. It's precise, potent, and tissue-targeted in a way few fat-loss compounds can claim.
🔬 What the Research Shows
The landmark study in obese rhesus monkeys produced some of the most dramatic fat-loss data in peptide research:
• Significant body weight reduction: Obese rhesus monkeys lost approximately 11% of total body weight over just 4 weeks of treatment — without dietary changes.
• Targeted fat loss: Imaging confirmed preferential reduction of white adipose tissue, with visceral and subcutaneous fat both affected. Lean mass was largely preserved.
• Improved insulin sensitivity: Weight loss was accompanied by improvements in metabolic markers, including reduced fasting insulin and improved glucose tolerance.
⚠️ Renal toxicity observed: The same study documented reversible kidney toxicity at the doses used. Renal function normalized after treatment was stopped, but this finding has significantly slowed progression toward human trials.
❇️ How It Differs From Other Fat-Loss Peptides
GLP-1 receptor agonists like Semaglutide work centrally — they regulate appetite and slow gastric emptying. AOD-9604 modulates fat metabolism through growth hormone receptor pathways. 5-Amino-1MQ works by inhibiting NNMT to increase NAD+ and metabolic rate. Adipotide does none of that. It's a vascular-targeted tissue destruction approach, which is why the fat-loss data is so dramatic — and why the safety profile demands serious attention. It's among the most potent, least metabolically gentle compounds in this research category.
🧬 Research Protocols
⚠️ The following reflects parameters from published preclinical research.
🚨Given the renal toxicity signals, these are noted strictly for educational context:
• Typical studied dose range: 100–1,000 mcg/kg in rodent models; the primate study used approximately 1 mg/kg/day. Human-equivalent dosing has not been established in clinical trials.
• Frequency: Daily administration was used in the primary primate research over the 4-week study period.
• Route of administration: Subcutaneous injection in all published studies. The peptide's size and structure make oral bioavailability unlikely without specialized delivery systems.
• Cycle length: The landmark study ran 28 days continuously. Longer-term safety data in higher-order animals does not currently exist in the published literature.
• Stacking notes: No established combination protocols exist in the peer-reviewed literature. Given the renal considerations, stacking with nephrotoxic compounds would be a significant research concern. Some researchers have theorized pairing with renoprotective peptides (e.g., BPC-157) in preclinical models, though no direct data supports this.
✅ Bottom Line
Adipotide is one of the most fascinating and polarizing compounds in the research peptide landscape. The fat-loss mechanism is genuinely novel, and the primate data is hard to ignore. At the same time, the renal toxicity findings are a real limitation that explain why this compound hasn't advanced to human trials. For researchers, it represents an important case study in targeted vascular approaches to body composition — with both the promise and the caution that comes with that territory.
✅ This article is for educational purposes only. All compounds discussed are for research use only and are not approved for human use. Nothing in this article constitutes medical advice. Always consult a licensed healthcare professional before making any health decisions.
4
0 comments
Adipotide (FTPP): The Proapoptotic Peptide That Targets Fat at the Source
powered by
skool.com/peptide-resource-center-3431
We are here for you because we've been there. Get support, education, resources and more!!!
Suggested communities
Powered by